Distinguished in Anemia

Dr. Sunil G. Gandhi

Florida Cancer Specialists And Research Institute, LLC
Lecanto, FL
Distinguished
in Anemia
Specialties:Oncology | Hematology
Accepting New Patients
Offers Telehealth
43 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Sunil Gandhi is an Oncologist and a Hematologist in Lecanto, Florida. Dr. Gandhi has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Anal Cancer, Anemia, Familial Colorectal Cancer, Lung Cancer, and Bone Marrow Aspiration. Dr. Gandhi is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Hca Florida Citrus Hospital
Tampa General Hospital Crystal River
Languages Spoken
English
Hindi
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  Oscar
  •  Humana
  •  Florida Blue

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
521 N Lecanto Hwy, Florida Cancer Specialists Pl, Lecanto, FL 34461
352-746-0707

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

6 Total Publications

MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Journal: Radiology
Published: September 03, 2024
Similar Doctors
Expertise in
57
conditions
Dr. Andrew M. Weber
Hematology | Hospital Medicine | Hematology Oncology
Expertise in
57
conditions
Dr. Andrew M. Weber
Hematology | Hospital Medicine | Hematology Oncology

Ocala Oncology Center Pl

13940 Us Hwy 441 N, Suite 203, 
Lady Lake, FL 
 (35.1 mi)
352-259-8940
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Weber is a Hematologist and a Hospital Medicine provider in Lady Lake, Florida. Dr. Weber and is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Anemia. Dr. Weber is currently accepting new patients.

Expertise in
40
conditions
Dr. Sandeep K. Thaper
Oncology | Hematology
Expertise in
40
conditions
Dr. Sandeep K. Thaper
Oncology | Hematology

Florida Cancer Specialists And Research Institute, LLC

601 E Dixie Avenue, 1001 Florida Cancer Specialists Pl, 
Leesburg, FL 
 (37.6 mi)
352-787-9448
Languages Spoken:
English, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandeep Thaper is an Oncologist and a Hematologist in Leesburg, Florida. Dr. Thaper and is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Anemia. Dr. Thaper is currently accepting new patients.

Expertise in
18
conditions
Dr. Pablo C. Reyes
Oncology | Hematology
Expertise in
18
conditions
Dr. Pablo C. Reyes
Oncology | Hematology

Florida Cancer Specialists And Research Institute, LLC

1400 N Us Hwy 441 552, Florida Cancer Specialists Pl, 
Lady Lake, FL 
 (32.5 mi)
352-753-9777
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Pablo Reyes is an Oncologist and a Hematologist in Lady Lake, Florida. Dr. Reyes and is rated as an Advanced provider by MediFind in the treatment of Anemia. His top areas of expertise are Anemia, Pleuropulmonary Blastoma, Thrombocytopenia, and Lynch Syndrome. Dr. Reyes is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile